Form 8-K Phio Pharmaceuticals For: Mar 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500, Nasdaq set for weekly fall as chip stocks slide
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
Phio Pharmaceuticals signs manufacturing agreement for cancer drug
March 30, 2026 7:18 AM EDTPhio Pharmaceuticals Corp. (NASDAQ: PHIO) announced it has entered into a manufacturing services agreement with a U.S. manufacturer for clinical supply of its lead compound PH-762. The agreement covers both clinical and commercial supply manufacturing for future clinical trials.
The clinical-stage biopharmaceutical... More
